Abstract

Cancer cells acquire genetic heterogeneity to escape from immune surveillance during tumor evolution, but a systematic approach to distinguish driver from passenger mutations is lacking. Here we investigate the impact of different immune pressure on tumor clonal dynamics and immune evasion mechanism, by combining massive parallel sequencing of immune edited tumors and CRISPR library screens in syngeneic mouse tumor model and co-culture system. We find that the core microRNA (miRNA) biogenesis and targeting machinery maintains the sensitivity of cancer cells to PD-1-independent T cell-mediated cytotoxicity. Genetic inactivation of the machinery or re-introduction of ANKRD52 frequent patient mutations dampens the JAK-STAT-interferon-γ signaling and antigen presentation in cancer cells, largely by abolishing miR-155-targeted silencing of suppressor of cytokine signaling 1 (SOCS1). Expression of each miRNA machinery component strongly correlates with intratumoral T cell infiltration in nearly all human cancer types. Our data indicate that the evolutionarily conserved miRNA pathway can be exploited by cancer cells to escape from T cell-mediated elimination and immunotherapy.

Dysregulation of the microRNA machinery has crucial roles in cancer development. Here the authors show that inactivation of proteins involved in microRNA-mediated gene silencing, such as ANKRD52 or AGO2, confers resistance to T cell-mediated immune response in a preclinical cancer model.

Details

Title
Tumor evolution selectively inactivates the core microRNA machinery for immune evasion
Author
Tian-Yu, Song 1   VIAFID ORCID Logo  ; Long, Min 2 ; Hai-Xin, Zhao 3 ; Miao-Wen, Zou 4   VIAFID ORCID Logo  ; Hong-Jie, Fan 5 ; Liu, Yang 4 ; Chen-Lu, Geng 2 ; Min-Fang, Song 6 ; Yu-Feng, Liu 4 ; Jun-Yi, Chen 4 ; Yu-Lin, Yang 7 ; Wen-Rong, Zhou 7 ; Da-Wei, Huang 7 ; Peng, Bo 4 ; Zhen-Gang, Peng 7 ; Cang Yong 4   VIAFID ORCID Logo 

 Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China (GRID:grid.440637.2) (ISNI:0000 0004 4657 8879); Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China (GRID:grid.507739.f) (ISNI:0000 0001 0061 254X); Zhejiang University, Life Sciences Institute, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X) 
 Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China (GRID:grid.440637.2) (ISNI:0000 0004 4657 8879); Zhejiang University, Life Sciences Institute, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X) 
 Oncology and Immunology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd, Shanghai, China (GRID:grid.13402.34) 
 Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China (GRID:grid.440637.2) (ISNI:0000 0004 4657 8879) 
 Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China (GRID:grid.440637.2) (ISNI:0000 0004 4657 8879); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419) 
 Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China (GRID:grid.440637.2) (ISNI:0000 0004 4657 8879); Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China (GRID:grid.507739.f) (ISNI:0000 0001 0061 254X); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419) 
 Oncology and Immunology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd, Shanghai, China (GRID:grid.440637.2) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2604986218
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.